Check out the latest scientific presentations from Kailera Therapeutics.
September 2024
Efficacy and Safety of HRS9531, a Novel Dual GLP-1/GIP Receptor agonist, in Patients with Type 2 Diabetes Mellitus (T2DM): A Phase 2 Trial
European Association for the Study of Diabetes (EASD) 2024
June 2024
Efficacy and Safety of HRS9531, a Novel Dual GLP-1/GIP Receptor Agonist, in Obese Adults: A Phase 2 Trial
American Diabetes Association (ADA) 2024
December 2023
Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of a Dual GLP-1/GIP Receptor Agonist HRS9531 in T2DM patients: A Randomized, Double-blind, Placebo and Open-label Positive-controlled Phase 1b Trial
International Diabetes Federation (IDF) 2023
June 2023
Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of a Dual GLP-1/GIP Receptor Agonist (HRS9531) in Healthy Subjects: A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose (SAD and MAD) Study
American Diabetes Association (ADA) 2023
June 2023
Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of a Novel Oral Small Molecule GLP-1 Receptor Agonist (HRS-7535) in Healthy Subjects: A Phase 1, Randomized, Double-blind, Placebo-controlled, Single- and Multiple-Ascending Dose (SAD and MAD) Study
American Diabetes Association's (ADA) 2023